Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 5/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220338 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL8815517 | 0.82 | PTGS1 (0.41) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL8815511 | 0.82 | PTGS1 (0.41) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL14789149 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL23138340 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL16259997 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL16260027 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| S-Nitrosoglutathione SCHEMBL6802668 | 0.77 | PTGS1 (0.64) | PTGS1GSTK1GLO1 | |
| S-Nitrosoglutathione SCHEMBL154575 | 0.76 | PTGS1 (0.67) | PTGS1GSTK1GLO1 | |
| S-Nitrosoglutathione SCHEMBL30637209 | 0.76 | PTGS1 (0.67) | PTGS1GSTK1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374562-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | EPICENTRX, INC. (US) | 2024-11-14 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| CN-107454849-B | Method for sterilizing S-nitrosothiols | 萨卢庞特咨询有限公司 | 2021-09-03 | — | — | CN | claimed |
| EP-3027180-B1 | COMPOSITIONS AND METHODS OF THE TREATMENT OF FATTY ACID METABOLISM DISORDERS | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2021-07-07 | — | — | EP | claimed |
| US-20190336602-A1 | STERILISATION OF S-NITROSOTHIOLS | Salupont Consulting Ltd. (GB) | 2019-11-07 | — | — | US | claimed |
| US-20180297931-A1 | Compositions and Methods for the Treatment of Fatty Acid Metabolism Disorders | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2018-10-18 | — | — | US | claimed |
| EP-3370714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FATTY ACID METABOLISM DISORDERS | The Children's Hospital of Philadelphia (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002034303-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2002-05-02 | — | — | WO | claimed |
| US-20010046471-A1 | Infrared thermograpy and methods of use | NICOX S.A. (FR) | 2001-11-29 | — | — | US | claimed |
| WO-2001085013-A2 | INFRARED THERMOGRAPHY AND METHODS OF USE | NITROMED, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | claimed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | claimed |
| US-6203789-B1 | TREATING ERYTHROCYTES WITH S-NITROSO-CYSTEINE, HOMOCYSTEINE, OR CYSTEINYLGLYCINE TO REDUCE BLOOD PRESSURE | DUKE UNIVERSITY | 2001-03-20 | — | — | US | claimed |
| US-6197745-B1 | USING AQUEOUS SOLUTION OF NITROSOTHIOL | DUKE UNIVERSITY | 2001-03-06 | — | — | US | claimed |
| US-6153186-A | LOADING OF RED BLOOD CELLS WITH A LOW MOLECULAR WEIGHT NITROSOTHIOL WHICH IS CAPABLE OF ENTERING THE RED BLOOD CELL AND CAUSING FORMATION OF S-NITROSYLATION OF THIOL GROUPS SUCH AS S-NITROSOCYSTEIN AND OTHER RELATED PEPTIDES | DUKE UNIVERSITY MEDICAL CENTER (US) | 2000-11-28 | — | — | US | claimed |
| WO-1997018000-A1 | S-NITROSO-HEMOGLOBIN AND THERAPEUTIC USES THEREOF | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1997-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336602-A1 | STERILISATION OF S-NITROSOTHIOLS | SULT1A1, SRM, SULT2A1 | ALDH1A1 285/4885MAPT 2914/4885LMNA 2947/4885 |
| US-20240374562-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | HBB, HBG2, HBZ | ALDH1A1 1464/4885MAPT 4665/4885LMNA 2548/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | ALDH1A1 334/4885MAPT 4664/4885LMNA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.